Author

Olusola Olusesan Faluyi

Observed names: Faluyi Olusola, Faluyi, O., O Faluyi, O O Faluyi, O. Faluyi, O. O. Faluyi, O.O. Faluyi, Olusola Faluyi, Olusola O Faluyi, Olusola O. Faluyi

Institution: Clatterbridge Cancer Centre NHS Foundation Trust

Observed institutions: University of Leeds, University Health Network, University of Liverpool, University of Toronto, Western General Hospital, Cancer Research UK, St James's University Hospital, Southampton General Hospital, Princess Margaret Cancer Centre, Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Hospital, Centre for Inflammation Research, The Queen's Medical Research Institute, Liverpool Experimental Cancer Medicine Centre, University College London, University of Edinburgh

ORCID: 0000-0001-6710-2210

Observed ORCID: 0000-0001-6710-2210

OpenAlex ID: A5033086853

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

2017 · John P Neoptolemos, Daniel H Palmer, et al. · The Lancet · 2,010

PDF

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

2019 · John N Primrose, Richard P Fox, et al. · The Lancet Oncology · 1,344

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

2019 · Robert P. Jones, Eftychia-Eirini Psarelli, et al. · JAMA Surgery · 297

PDF

TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

2020 · Daniel H. Palmer, Juan W. Valle, et al. · British Journal of Cancer · 74

PDF

Breast Radiotherapy for Occult Breast Cancer with Axillary Nodal Metastases — Does it Reduce the Local Recurrence Rate and Increase Overall Survival?

2010 · S.P. Masinghe, O.O. Faluyi, et al. · Clinical Oncology · 45

Interventions for the treatment of borderline ovarian tumours

2010 · Olusola Faluyi, Melanie Mackean, et al. · Cochrane Database of Systematic Reviews · 45

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

2024 · Daniel H. Palmer, Richard Jackson, et al. · Journal of Clinical Oncology · 41

Regulation of stromal cell cyclooxygenase-2 in the Apc Min/+ mouse model of intestinal tumorigenesis

2005 · M.A. Hull, O.O. Faluyi, et al. · Carcinogenesis · 29

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

2023 · Mairéad G. McNamara, Jayne Swain, et al. · EClinicalMedicine · 28

PDF

A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)

2020 · Mairéad G. McNamara, John Bridgewater, et al. · The Oncologist · 27

PDF

Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score

2017 · J. Edeline, J.-F. Blanc, et al. · European Journal of Cancer · 27

Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment

2013 · Lorin Dodbiba, Jennifer Teichman, et al. · Laboratory Investigation · 26

PDF

Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study

2018 · M K Doherty, Y Leung, et al. · Diseases of the Esophagus · 25

Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in Oncology patients with renal impairment

2011 · O. O. Faluyi, S. P. Masinghe, et al. · Medical Oncology · 22

Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial)

2019 · John K. Ramage, Pankaj Punia, et al. · Neuroendocrinology · 21

PDF

NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)

2020 · Zoe Craig, Jayne Swain, et al. · BMJ Open · 17

PDF

Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre

2017 · Olusola O Faluyi, Joanna L Connor, et al. · British Journal of Cancer · 15

PDF

Benefits of platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: A translational case series.

2012 · Olusola Olusesan Faluyi, Ben Tran, et al. · Journal of Clinical Oncology · 14

NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

2022 · Mairead Geraldine McNamara, Jayne Swain, et al. · Journal of Clinical Oncology · 13

Interventions for the treatment of borderline ovarian tumours

2009 · Olusola Faluyi, Melanie Mackean, et al. · Cochrane Database of Systematic Reviews · 13

Validation of micro RNA pathway polymorphisms in esophageal adenocarcinoma survival

2017 · Olusola O. Faluyi, Lawson Eng, et al. · Cancer Medicine · 11

PDF

An increased CD25-positive intestinal regulatory T lymphocyte population is dependent upon Cox-2 activity in the Apcmin/+ model

2017 · O O Faluyi, P Fitch, et al. · Clinical & Experimental Immunology · 9

Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome

2015 · Lawson Eng, Abul Kalam Azad, et al. · Carcinogenesis · 9

Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome

2017 · Grzegorz J. Korpanty, Lawson Eng, et al. · Oncotarget · 7

PDF

Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer.

2010 · Olusola O Faluyi, Charlie Gourley, et al. · PubMed · 7

Works count: 55

Citation count: 4,207

H-index: 16

I10-index: 21